A Phase 2 interventional study of Selinexor and Hydroxyurea in Acute Myeloid Leukemia (AML), sponsored by Karyopharm Therapeutics Inc. Completed at 78 sites in 11 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.
Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing selinexor in Leukemia, Myeloid, Acute — 6 open to participants now, 12 under way, 2 of them phase 3. selinexor · Leukemia, Myeloid, Acute.
Among the 27 studies testing selinexor in Leukemia, Myeloid, Acute, this one has the largest enrollment, is one of 5 that started in 2014, is one of 9 in phase 2, and was the 1st registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →6 of the 27 studies testing selinexor in Leukemia, Myeloid, Acute are open now, in 1 country. Recruiting first, the newest first:
Shanghai Tong Ren Hospital · Sites in China
Ages 18+
Shanxi Bethune Hospital · Sites in China
Ages 18–60
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 16–75
Ruijin Hospital · Sites in China
Ages 18–75
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 55+
By country, each count listing its studies:
selinexor: first FDA approval 2019 (XPOVIO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 13 · Phase 3 2
First in 2014; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 317 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 25 across the 27 interventional studies. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 27 have an industry lead sponsor. The 10 most frequent:
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Karyopharm Therapeutics Inc has 2 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
3 of the studies testing selinexor in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06613035Phase 3Institute of Hematology & Blood Diseases Hospital, ChinaTwice-per-weekSelinexor, 2 Days Melphalan | 2027-09-30 |
| NCT02835222Wake Forest University Health SciencesSelinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients | 2027-04-18 |
| NCT07094464Daihong LiuMaintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies testing selinexor in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, multicenter, open-label, phase 2 study of the SINE compound, selinexor given orally versus specified investigator choices (one of three potential salvage therapies). Participants age ≥ 60 years with relapsed or refractory AML of any type except for AML M3, after one prior therapy only, who have never undergone and who are not currently eligible for stem cell transplantation and are currently deemed unfit for intensive chemotherapy.
This is a randomized, multicenter, open-label phase 2 study of the SINE compound, selinexor given orally versus restricted investigator choice (i.e., one of three potential salvage therapies).
Participants who have never been transplant eligible, are currently deemed unfit for intensive chemotherapy, ≥ 60 years old, who have AML (except Acute Promyelocytic Leukemia: APL, AML M3) after one prior treatment of either hypomethylating agent or a regimen including Ara-C, and are meeting the inclusion and exclusion criteria will be randomized to receive either oral selinexor or physician's choice (one of three potential treatments: best supportive care (BSC) alone, or BSC + hypomethylating agent, or BSC + low dose Ara-C until disease progression, death or intolerance has occurred.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants under protocol versions (PV) less than (\<) 5.0 (those who had one prior line of acute myeloid leukemia (AML) therapy), receive oral selinexor tablets at a dose of approximately 55 mg/m\^2 (milligrams per square meter) (60 to 120 mg based on body surface area \[BSA\]) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
Drug: Selinexor
Participants under PV \< 5.0 (those who had one prior line of AML therapy), receive oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m\^2), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
Drug: Selinexor
Participants under PV \>= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), receive oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m\^2) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
Drug: Selinexor
Participants under PV \< 5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.
Drug: Hydroxyurea
Participants under PV \>= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.
Drug: Ara-C
Selinexor oral tablet.
Also known as: KPT-330
Also known as: Hydroxycarbamide
Ara-C Subcutaneous Injection.
Also known as: Cytarabine, Cytosine arabinoside, Cytosar-U, Depocyt
Overall Survival
Overall survival was defined as the time (in days) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact.
Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Percentage of Participants With Overall Survival of at Least 3 Months (OS3.0)
Overall survival was defined as the time (in days) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.
Time frame: From randomization (Day 1) up to 3 months
Percentage of Participants With Complete Remission Rate (CRR) for Those Who Achieved Complete Remission (CR)
CRR was analyzed using International Working Group (IWG) 2003 criteria, as the difference in the proportions of participants with IWG results of CR. CR per IWG 2003 criteria was defined as morphologic presence of \< 5 percentage (%) myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood absolute neutrophil count (ANC) \> 1000 cells/microliter (microL) and platelet count \> 100,000/microL, with no need for red blood cell (RBC) transfusions), and the absence of extramedullary disease.
Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Median Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission (CR)
DFS for CRR based on IWG criteria, was calculated from the first date of response of CR to the date of progression or recurrence, or date of death if progression or recurrence did not occur. Participants who discontinued prior to disease progression or recurrence or did not progress as of the time of the analysis were censored at the time of last radiologic assessment. CR per IWG 2003 criteria was defined as morphologic presence of \< 5 % myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC \> 1000 cells/microL and platelet count \> 100,000/microL, with no need for RBC transfusions), and the absence of extramedullary disease.
Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Percentage of Participants With Modified Complete Remission Rate (mCRR) for Those Who Achieved Complete Remission (CR) or Complete Remission With Incomplete Hematologic Recovery (Cri)
mCRR was defined as the point estimate of the percentage of participants who had CR, CRi, or CRp. Responses defined as per IWG 2003 response criteria: Morphologic CR:\< 5% myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC \> 1000 cells/microL and platelet count \> 100,000/microL, with no need for RBC transfusions), and the absence of extramedullary disease. Morphologic CRp: All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L), Cri (\< 5% bone marrow blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]), normal maturation of all cellular components in the bone marrow, no extramedullary disease and transfusion independent.
Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Median Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission or CR With Incomplete Hematologic Recovery (CRi) or Complete Remission With Incomplete Platelet Recovery (CRp)
DFS based on IWG criteria was defined as the duration from start of the complete response achieved until disease progression or death from any cause. Responses defined by IWG 2003 Response Criteria: Morphologic CR: \< 5% myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC \> 1000 cells/microL and platelet count \> 100,000/microL, with no need for RBC transfusions), and the absence of extramedullary disease. Morphologic CRp: All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L), Cri (\< 5% bone marrow blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]), normal maturation of all cellular components in the bone marrow, no extramedullary disease and transfusion independent.
Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Percentage of Participants With Overall Response Rate (ORR)
Overall response rate was defined as the point estimate of the percentage of participants who achieved CR (disappearance of all target and non-target lesions), partial response (PR) (\>=30 % decrease in sum of longest diameters of target lesions taking as reference baseline sum longest diameters associated to non-progressive disease response for non-target lesions). CRi; \< 5% BM blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. CRp; All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L) and morphologic leukemia-free state (MLFS); morphologic BM blast clearance to \<5% in a marrow sample in which \<=200 cells enumerated or cellularity is ≥10%, in absence of blasts with Auer rods, no hematologic recovery required.
Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Duration of Response (DOR)
DOR was calculated from date of response of CR, CRi, CRp, MLFS, or PR to date of progression or recurrence based on IWG criteria. CR: \<5% myeloblasts in bone marrow,absence of circulating blasts, hematologic recovery (peripheral blood ANC \>1000 cells/microL, platelet count \> 100,000/microL, no need for RBC transfusions), absence of extramedullary disease. PR: No circulating blasts, neutrophil count \> =1.0 x10\^9/L, platelet count \>= 100 x10\^9/L, \>= 50 % reduction in bone marrow blast to 6% to 25%, or blasts less than or equal to (\<=) 5% if Auer rods are present. CRp: All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L), CRi; \< 5% bone marrow blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. MLFS: morphologic bone marrow blast clearance to \< 5% in marrow sample, \<= 200 cells enumerated/cellularity is ≥ 10%, in absence of blasts with Auer rods, no hematologic recovery required.
Time frame: Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks)
Percentage of Participants With Disease Control Rate (DCR)
DCR:Point estimate of % of participants with CR,CRi,CRp,MLFS,PR, or SD for \<=4 weeks.CR:\<5% myeloblasts in bone marrow (BM),absence of circulating blasts,hematologic recovery(peripheral blood ANC \>1000 cells/microL and platelet count \>100,000/microL, no need of RBC transfusions),absence of extramedullary disease. PR:No circulating blasts,Neutrophil count \>=1.0 x10\^9/L, Platelet count \>= 100\*10\^9/L, \>=50% reduction in BM blast to 6% to 25%, or blasts \<=5% if Auer rods are present.CRp:All criteria for CR except for residual neutropenia (\<1\*10\^9/L) or thrombocytopenia(\<100 x10\^9/L),CRi;\< 5% BM blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. MLFS:morphologic BM blast clearance to \<5% in a marrow sample in which \<=200 cells enumerated or cellularity is ≥10%,in absence of blasts with Auer rods,no hematologic recovery required,SD:failure to achieve a response but not meeting criteria for disease progression over period of \>4 weeks.
Time frame: Up to 4 weeks from the date of randomization to the date of progression or recurrence based on IWG criteria
Duration of Disease Control Rate
Duration of DCR calculated for all participants with DCR. CR: \< 5% myeloblasts in BM, absence of circulating blasts, hematologic recovery (peripheral blood ANC \>1000 cells/microL and platelet count \> 100,000/microL, no need for RBC transfusions), absence of extra medullary disease. PR: No circulating blasts, Neutrophil count \>=1.0 x 10\^9/L, Platelet count \>= 100 x 10\^9/L, \>= 50 % reduction in BM blast to 6% to 25%, or blasts \<= 5% if Auer rods are present. CRp: All criteria for CR except for residual neutropenia (\<1 x 10\^9/L) or thrombocytopenia (\<100 x 10\^9/L), CRi; \< 5% BM blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. MLFS; morphologic BM blast clearance to \< 5% in a marrow sample in which \<=200 cells enumerated/cellularity is \>= 10%, in absence of blasts with Auer rods, no hematologic recovery required and SD; failure to achieve a response but not meeting criteria for disease progression over period of \> 4 weeks.
Time frame: Up to 4 weeks from the date of randomization to the date of progression or recurrence based on IWG criteria
Change From Baseline in Quality of Life (QoL) and Patient-Reported Outcomes (Functional Assessment of Cancer Therapy -Leukemia [FACT-Leu]
QoL was assessed by the FACT-Leu. FACT-Leu combines the General version of the Functional Assessment of Cancer Therapy (FACT-G) with a leukemia-specific sub-scale (17 items). The sub-scales for the FACT-G are Physical Well-Being (7 items), Social/Family Well-Being (7 items), Emotional Well-Being (6 items), and Functional Well-Being (7 items). The trial outcomes index (TOI; total of 31 items) was the primary measurement of interest, comprising the Physical and Functional sub-scales plus the leukemia - specific sub-scale. Each item was rated on a 5-point Likert scale. Range from 0 = (Not at all) to 4 = (Very much); therefore, the TOI had a score ranging from 0 to 124. Higher scores indicated improvement in well being. The QoL assessment was performed at baseline (prior to first dose of study treatment), Day 1 of each cycle on or after the second, and at the final visit.
Time frame: Baseline, Day 1 of each treatment cycle (a maximum of 20 cycles: 28 days per cycle) up to 30 days after last dose of study drug (final visit)
Change From Baseline in European Quality of Life-5 Dimension (EQ-5D) Health Questionnaire Visual Analogue Scale (VAS)
EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ VAS. EQ-5D-5-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable), higher scores indicating a better health state.
Time frame: Baseline, Day 1 of each treatment cycle (a maximum of 20 cycles: 28 days per cycle) up to 30 days after last dose of study drug (final visit)
| Milestone | Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA) | Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2) | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 1 (PV <5) | Physician's Choice 2 (PV >=5) |
|---|---|---|---|---|---|
| Started | 71 | 27 | 117 | 44 | 58 |
| Safety population | 71 | 27 | 115 | 39 | 45 |
| Intent-to-treat (itt) population | 0 | 0 | 118 | 0 | 57 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 71 | 27 | 117 | 44 | 58 |
| Withdrew: Adverse event | 3 | 0 | 3 | 3 | 0 |
| Withdrew: Death | 51 | 21 | 85 | 28 | 38 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 2 | 1 | 2 | 0 | 2 |
| Withdrew: Disease progression | 7 | 1 | 2 | 3 | 1 |
| Withdrew: Study terminated by sponsor | 1 | 1 | 12 | 2 | 6 |
| Withdrew: Withdrawal by subject | 3 | 2 | 9 | 7 | 10 |
| Withdrew: Other | 2 | 1 | 3 | 1 | 1 |
Overall survival was defined as the time (in days) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact.
| Days | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 2 (PV >=5) |
|---|---|---|
| Overall Survival | 94.0 (78.0 to 158.0) | 170.0 (111.0 to 220.0) |
Overall survival was defined as the time (in days) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.
| Percentage of participants | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 2 (PV >=5) |
|---|---|---|
| Percentage of Participants With Overall Survival of at Least 3 Months (OS3.0) | 53.49 (43.54 to 62.44) | 70.73 (55.60 to 81.52) |
CRR was analyzed using International Working Group (IWG) 2003 criteria, as the difference in the proportions of participants with IWG results of CR. CR per IWG 2003 criteria was defined as morphologic presence of \< 5 percentage (%) myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood absolute neutrophil count (ANC) \> 1000 cells/microliter (microL) and platelet count \> 100,000/microL, with no need for red blood cell (RBC) transfusions), and the absence of extramedullary disease.
| Percentage of participants | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 2 (PV >=5) |
|---|---|---|
| Percentage of Participants With Complete Remission Rate (CRR) for Those Who Achieved Complete Remission (CR) | 5.1 (1.9 to 10.7) | 0 (0.0 to 6.3) |
DFS for CRR based on IWG criteria, was calculated from the first date of response of CR to the date of progression or recurrence, or date of death if progression or recurrence did not occur. Participants who discontinued prior to disease progression or recurrence or did not progress as of the time of the analysis were censored at the time of last radiologic assessment. CR per IWG 2003 criteria was defined as morphologic presence of \< 5 % myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC \> 1000 cells/microL and platelet count \> 100,000/microL, with no need for RBC transfusions), and the absence of extramedullary disease.
| Days | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 2 (PV >=5) |
|---|---|---|
| Median Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission (CR) | 121.0 (49.0 to NA) | — |
mCRR was defined as the point estimate of the percentage of participants who had CR, CRi, or CRp. Responses defined as per IWG 2003 response criteria: Morphologic CR:\< 5% myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC \> 1000 cells/microL and platelet count \> 100,000/microL, with no need for RBC transfusions), and the absence of extramedullary disease. Morphologic CRp: All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L), Cri (\< 5% bone marrow blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]), normal maturation of all cellular components in the bone marrow, no extramedullary disease and transfusion independent.
| Percentage of participants | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 2 (PV >=5) |
|---|---|---|
| Percentage of Participants With Modified Complete Remission Rate (mCRR) for Those Who Achieved Complete Remission (CR) or Complete Remission With Incomplete Hematologic Recovery (Cri) | 11.9 (6.6 to 19.1) | 3.5 (0.4 to 12.1) |
DFS based on IWG criteria was defined as the duration from start of the complete response achieved until disease progression or death from any cause. Responses defined by IWG 2003 Response Criteria: Morphologic CR: \< 5% myeloblasts in bone marrow, the absence of circulating blasts, hematologic recovery (as evidenced by a peripheral blood ANC \> 1000 cells/microL and platelet count \> 100,000/microL, with no need for RBC transfusions), and the absence of extramedullary disease. Morphologic CRp: All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L), Cri (\< 5% bone marrow blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]), normal maturation of all cellular components in the bone marrow, no extramedullary disease and transfusion independent.
| Days | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 2 (PV >=5) |
|---|---|---|
| Median Disease-Free Survival (DFS) for Participants Who Achieved Complete Remission or CR With Incomplete Hematologic Recovery (CRi) or Complete Remission With Incomplete Platelet Recovery (CRp) | 175.0 (61.0 to 288.0) | 106.0 (NA to NA) |
Overall response rate was defined as the point estimate of the percentage of participants who achieved CR (disappearance of all target and non-target lesions), partial response (PR) (\>=30 % decrease in sum of longest diameters of target lesions taking as reference baseline sum longest diameters associated to non-progressive disease response for non-target lesions). CRi; \< 5% BM blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. CRp; All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L) and morphologic leukemia-free state (MLFS); morphologic BM blast clearance to \<5% in a marrow sample in which \<=200 cells enumerated or cellularity is ≥10%, in absence of blasts with Auer rods, no hematologic recovery required.
| Percentage of participants | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 2 (PV >=5) |
|---|---|---|
| Percentage of Participants With Overall Response Rate (ORR) | 13.6 (8.0 to 21.1) | 8.8 (2.9 to 19.3) |
DOR was calculated from date of response of CR, CRi, CRp, MLFS, or PR to date of progression or recurrence based on IWG criteria. CR: \<5% myeloblasts in bone marrow,absence of circulating blasts, hematologic recovery (peripheral blood ANC \>1000 cells/microL, platelet count \> 100,000/microL, no need for RBC transfusions), absence of extramedullary disease. PR: No circulating blasts, neutrophil count \> =1.0 x10\^9/L, platelet count \>= 100 x10\^9/L, \>= 50 % reduction in bone marrow blast to 6% to 25%, or blasts less than or equal to (\<=) 5% if Auer rods are present. CRp: All criteria for CR except for residual neutropenia (\<1x10\^9/L) or thrombocytopenia (\<100 x10\^9/L), CRi; \< 5% bone marrow blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. MLFS: morphologic bone marrow blast clearance to \< 5% in marrow sample, \<= 200 cells enumerated/cellularity is ≥ 10%, in absence of blasts with Auer rods, no hematologic recovery required.
| Days | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 2 (PV >=5) |
|---|---|---|
| Duration of Response (DOR) | 204.0 (117.0 to 334.0) | 148.0 (85.0 to NA) |
DCR:Point estimate of % of participants with CR,CRi,CRp,MLFS,PR, or SD for \<=4 weeks.CR:\<5% myeloblasts in bone marrow (BM),absence of circulating blasts,hematologic recovery(peripheral blood ANC \>1000 cells/microL and platelet count \>100,000/microL, no need of RBC transfusions),absence of extramedullary disease. PR:No circulating blasts,Neutrophil count \>=1.0 x10\^9/L, Platelet count \>= 100\*10\^9/L, \>=50% reduction in BM blast to 6% to 25%, or blasts \<=5% if Auer rods are present.CRp:All criteria for CR except for residual neutropenia (\<1\*10\^9/L) or thrombocytopenia(\<100 x10\^9/L),CRi;\< 5% BM blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. MLFS:morphologic BM blast clearance to \<5% in a marrow sample in which \<=200 cells enumerated or cellularity is ≥10%,in absence of blasts with Auer rods,no hematologic recovery required,SD:failure to achieve a response but not meeting criteria for disease progression over period of \>4 weeks.
| Percentage of participants | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 2 (PV >=5) |
|---|---|---|
| Percentage of Participants With Disease Control Rate (DCR) | 50.8 (41.5 to 60.2) | 40.4 (27.6 to 54.2) |
Duration of DCR calculated for all participants with DCR. CR: \< 5% myeloblasts in BM, absence of circulating blasts, hematologic recovery (peripheral blood ANC \>1000 cells/microL and platelet count \> 100,000/microL, no need for RBC transfusions), absence of extra medullary disease. PR: No circulating blasts, Neutrophil count \>=1.0 x 10\^9/L, Platelet count \>= 100 x 10\^9/L, \>= 50 % reduction in BM blast to 6% to 25%, or blasts \<= 5% if Auer rods are present. CRp: All criteria for CR except for residual neutropenia (\<1 x 10\^9/L) or thrombocytopenia (\<100 x 10\^9/L), CRi; \< 5% BM blasts with residual neutropenia \[ANC \< 1000 cells/microL\] or thrombocytopenia \[platelets \< 100,000/microL\]. MLFS; morphologic BM blast clearance to \< 5% in a marrow sample in which \<=200 cells enumerated/cellularity is \>= 10%, in absence of blasts with Auer rods, no hematologic recovery required and SD; failure to achieve a response but not meeting criteria for disease progression over period of \> 4 weeks.
| Days | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 2 (PV >=5) |
|---|---|---|
| Duration of Disease Control Rate | 187.0 (125.0 to 261.0) | 233.0 (155.0 to 263.0) |
QoL was assessed by the FACT-Leu. FACT-Leu combines the General version of the Functional Assessment of Cancer Therapy (FACT-G) with a leukemia-specific sub-scale (17 items). The sub-scales for the FACT-G are Physical Well-Being (7 items), Social/Family Well-Being (7 items), Emotional Well-Being (6 items), and Functional Well-Being (7 items). The trial outcomes index (TOI; total of 31 items) was the primary measurement of interest, comprising the Physical and Functional sub-scales plus the leukemia - specific sub-scale. Each item was rated on a 5-point Likert scale. Range from 0 = (Not at all) to 4 = (Very much); therefore, the TOI had a score ranging from 0 to 124. Higher scores indicated improvement in well being. The QoL assessment was performed at baseline (prior to first dose of study treatment), Day 1 of each cycle on or after the second, and at the final visit.
| Units on a scale | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 2 (PV >=5) |
|---|---|---|
| Baseline | 70.5 ± 15.20 | 75.4 ± 14.74 |
| C2D1 | 0.5 ± 16.50 | -1.9 ± 15.18 |
| C3D1 | -1.9 ± 16.88 | -5.4 ± 22.25 |
| C4D1 | -1.2 ± 15.70 | -7.4 ± 25.41 |
| C5D1 | -2.4 ± 16.84 | 1.9 ± 8.40 |
| C6D1 | -3.4 ± 15.66 | -4.7 ± 13.20 |
| C7D1 | -5.0 ± 17.21 | -11.8 ± 27.43 |
| C8D1 | -3.9 ± 15.78 | -10.6 ± 7.83 |
| C9D1 | -2.7 ± 7.47 | -8.0 ± 8.49 |
| C10D1 | 2.4 ± 13.19 | -10.7 ± 12.70 |
| C11D1 | -0.1 ± 8.65 | -10.0 ± 9.90 |
| C12D1 | -3.7 ± 11.69 | -7.0 ± 16.97 |
| C13D1 | -3.3 ± 6.40 | -9.0 ± NA |
| C14D1 | -4.0 ± 3.46 | -15.0 |
| C15D1 | 1.5 ± 3.54 | -10.0 ± NA |
| C16D1 | — | -15.0 ± NA |
| C17D1 | -15.0 ± NA | -7.0 ± NA |
| C18D1 | -1.0 ± NA | — |
| C19D1 | -12.0 ± NA | — |
| C20D1 | -14.0 ± NA | — |
| Final visit | 2.5 ± 17.71 | -1.7 ± 20.46 |
EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ VAS. EQ-5D-5-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable), higher scores indicating a better health state.
| Units on a scale | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 2 (PV >=5) |
|---|---|---|
| Baseline | 67.9 ± 19.51 | 63.5 ± 21.10 |
| C2D1 | -7.5 ± 23.45 | 0.8 ± 15.82 |
| C3D1 | -13.3 ± 25.04 | -5.2 ± 23.54 |
| C4D1 | -6.1 ± 20.80 | -5.0 ± 11.46 |
| C5D1 | -0.9 ± 20.83 | -2.0 ± 15.31 |
| C6D1 | -11.2 ± 25.90 | -1.4 ± 24.10 |
| C7D1 | -3.7 ± 23.91 | 4.0 ± 10.84 |
| C8D1 | 0.1 ± 16.77 | 5.0 ± 9.35 |
| C9D1 | 4.6 ± 13.25 | 5.0 ± 10.80 |
| C10D1 | 0.7 ± 18.58 | 6.3 ± 15.48 |
| C11D1 | 0.8 ± 18.55 | -5.0 ± 21.21 |
| C12D1 | 3.3 ± 16.63 | -5.0 ± 28.28 |
| C13D1 | 6.7 ± 20.21 | 10.0 ± NA |
| C14D1 | 6.7 ± 25.66 | 15.0 ± NA |
| C15D1 | 3.5 ± 30.41 | -10.0 ± NA |
| C16D1 | — | 20.0 ± NA |
| C17D1 | 25.0 ± NA | -5.0 ± NA |
| C18D1 | 25.0 ± NA | — |
| C19D1 | 30.0 ± NA | — |
| C20D1 | 35.0 ± NA | — |
Collected over From start of study drug administration to 30 days after last dose of study drug (approximately 48 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA) | 24/71 (33.8%) | 58/71 (81.7%) | 71/71 (100%) |
| Selinexor 60mg (PV<5) (Equivalent to 35 mg/m^2) | 3/27 (11.1%) | 15/27 (55.6%) | 27/27 (100%) |
| Selinexor 60mg (PV >=5) (Equivalent to 35 mg/m^2) | 28/115 (24.3%) | 89/115 (77.4%) | 113/115 (98.3%) |
| Physician's Choice 1 (PV <5) | 7/39 (17.9%) | 25/39 (64.1%) | 37/39 (94.9%) |
| Physician's Choice 2 (PV >=5) | 9/45 (20%) | 30/45 (66.7%) | 40/45 (88.9%) |
| Event | Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA) | Selinexor 60mg (PV<5) (Equivalent to 35 mg/m^2) | Selinexor 60mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 1 (PV <5) | Physician's Choice 2 (PV >=5) |
|---|---|---|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 16/71 | 4/27 | 20/115 | 8/39 | 16/45 |
| PneumoniaInfections and infestations | 10/71 | 4/27 | 10/115 | 4/39 | 3/45 |
| Nervous System DisordersNervous system disorders | 8/71 | 1/27 | 15/115 | 0/39 | 1/45 |
| SepsisInfections and infestations | 8/71 | 1/27 | 3/115 | 3/39 | 1/45 |
| Lung InfectionInfections and infestations | 3/71 | 1/27 | 1/115 | 3/39 | 0/45 |
| DehydrationMetabolism and nutrition disorders | 5/71 | 0/27 | 2/115 | 1/39 | 0/45 |
| HyperglycaemiaMetabolism and nutrition disorders | 5/71 | 0/27 | 0/115 | 0/39 | 0/45 |
| FatigueGeneral disorders | 1/71 | 0/27 | 8/115 | 0/39 | 0/45 |
| AnaemiaBlood and lymphatic system disorders | 2/71 | 0/27 | 2/115 | 0/39 | 3/45 |
| PyrexiaGeneral disorders | 4/71 | 1/27 | 7/115 | 2/39 | 1/45 |
| Event | Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA) | Selinexor 60mg (PV<5) (Equivalent to 35 mg/m^2) | Selinexor 60mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 1 (PV <5) | Physician's Choice 2 (PV >=5) |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 41/71 | 16/27 | 68/115 | 13/39 | 8/45 |
| Decreased AppetiteGeneral disorders | 41/71 | 12/27 | 61/115 | 9/39 | 7/45 |
| DiarrhoeaGastrointestinal disorders | 17/71 | 13/27 | 41/115 | 8/39 | 6/45 |
| FatigueGeneral disorders | 33/71 | 13/27 | 50/115 | 15/39 | 13/45 |
| ThrombocytopeniaBlood and lymphatic system disorders | 29/71 | 7/27 | 38/115 | 18/39 | 11/45 |
| AnaemiaBlood and lymphatic system disorders | 20/71 | 7/27 | 29/115 | 17/39 | 10/45 |
| ConstipationGastrointestinal disorders | 20/71 | 8/27 | 25/115 | 16/39 | 15/45 |
| VomitingGastrointestinal disorders | 19/71 | 10/27 | 30/115 | 7/39 | 6/45 |
| HyponatraemiaMetabolism and nutrition disorders | 26/71 | 6/27 | 25/115 | 3/39 | 1/45 |
| PyrexiaGeneral disorders | 8/71 | 5/27 | 28/115 | 13/39 | 13/45 |
Safety Population included all participants who received any amount of study treatment and was the primary population for the analysis of safety outcome measure.
| Age, Continuous(years) | Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA) | Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m^2) | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 1 (PV <5) | Physician's Choice 2 (PV >=5) | Total |
|---|---|---|---|---|---|---|
| Mean | 72.4 ± 6.49 | 73.2 ± 4.64 | 73.6 ± 5.99 | 72.6 ± 5.24 | 74.2 ± 5.92 | 73.2 ± 5.90 |
| Sex: Female, Male(Participants) | Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA) | Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m^2) | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 1 (PV <5) | Physician's Choice 2 (PV >=5) | Total |
|---|---|---|---|---|---|---|
| Female | 26 | 11 | 46 | 17 | 15 | 115 |
| Male | 45 | 16 | 69 | 22 | 30 | 182 |
| Ethnicity (NIH/OMB)(Participants) | Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA) | Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m^2) | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 1 (PV <5) | Physician's Choice 2 (PV >=5) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 9 | 4 | 6 | 26 |
| Not Hispanic or Latino | 65 | 23 | 93 | 34 | 31 | 246 |
| Unknown or Not Reported | 2 | 1 | 13 | 1 | 8 | 25 |
| Race/Ethnicity, Customized(Count of Participants) | Selinexor Approximately 55 mg/m^2 (60 to 120 mg Based on BSA) | Selinexor 60 mg (PV<5) (Equivalent to 35 mg/m^2) | Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2) | Physician's Choice 1 (PV <5) | Physician's Choice 2 (PV >=5) | Total |
|---|---|---|---|---|---|---|
| White | 67 | 22 | 95 | 39 | 37 | 260 |
| Black or African American | 3 | 1 | 3 | 0 | 0 | 7 |
| Asian | 0 | 2 | 0 | 0 | 0 | 2 |
| Other | 0 | 1 | 15 | 0 | 6 | 22 |
| Unknown | 1 | 1 | 2 | 0 | 2 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
The record gives a start of Mar 2014, a primary completion of Jan 2018 and a completion of Jan 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2020, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selinexor